Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China

Abstract Background To investigate the treatment pattern, adverse events, and quality of life of Chinese patients treated with CDK4/6 inhibitors (CDK4/6i) for hormone receptor (HR)+/HER2- advanced breast cancer. Methods This multicenter cross-sectional survey enrolled patients with HR+/HER2- advance...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-05-01
Colecção:	BMC Cancer
Assuntos:	Abemaciclib Advanced breast cancer Dalpiciclib Palbociclib Ribociclib
Acesso em linha:	https://doi.org/10.1186/s12885-025-14223-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!